Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023)
Cartesian Therapeutics' (RNAC) quarterly Preferred Stock Liabilities came in at $296.9 million in Q4 2023, up 5837.02% on a QoQ basis from $5.0 million in Q2 2016.
Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023) Analysis & Trends
Cartesian Therapeutics (RNAC) has 3 years of Preferred Stock Liabilities data on file, last reported at $296.9 million in Q4 2023.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $296.9 million in Q4 2023; TTM through Dec 2023 was $296.9 million, a N/A change from a year earlier, with the FY2023 full-year figure at $296.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2023 stood at $296.9 million, up from $5.0 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for RNAC reached as high as $296.9 million in Q4 2023 and fell as low as $296.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cartesian Therapeutics | 226.07 Mn | 226.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 296.85 Mn |
| Jun 30, 2016 | 5.00 Mn |
| Dec 31, 2015 | 137.48 Mn |